We are proud to announce the launch of Apremilast 10 mg, 20 mg, and 30 mg tablets in Europe. 💊
Developed and manufactured in-house by Tiefenbacher Group, Apremilast is indicated for the treatment of active psoriatic arthritis, oral ulcers associated with Behcet’s disease, and plaque psoriasis of any severity in patients who are candidates for phototherapy or systemic therapy – conditions that can have significant impact on patients’ daily lives. From visible skin symptoms and joint pain to painful oral ulcers that can affect basic social interactions, patients often face challenges that go far beyond the disease itself.
Following successful launches in international markets, Apremilast is now being introduced by our partners, with further launches planned across key European markets. 🌍
This milestone reflects our commitment to improving patients’ lives through better therapies, better access, and better affordability. 💙
